

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9652246/publications.pdf>

Version: 2024-02-01

57
papers

5,866
citations

66250

44
h-index

169272

56
g-index

58
all docs

58
docs citations

58
times ranked

5182
citing authors

#	ARTICLE	IF	CITATIONS
1	Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. <i>Andrology</i> , 2021, 9, 88-98.	1.9	283
2	Testosterone and Benign Prostatic Hyperplasia. <i>Sexual Medicine Reviews</i> , 2019, 7, 259-271.	1.5	68
3	Reply to Jae Heon Kim's Letter to the Editor re: Mauro Gacci, Giovanni Corona, Arcangelo Sebastianelli, et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:788-96. <i>European Urology</i> , 2017, 71, e119-e120.	0.9	0
4	Testosterone Replacement Therapy: Long-Term Safety and Efficacy. <i>World Journal of Men's Health</i> , 2017, 35, 65.	1.7	48
5	Influence of Androgen Receptor Gene CAG and GGC Polymorphisms on Male Sexual Function: A Cross-Sectional Study. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-7.	0.6	5
6	Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 788-796.	0.9	84
7	Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. <i>Nature Reviews Urology</i> , 2016, 13, 108-119.	1.9	98
8	Endocrinologic Control of Men's Sexual Desire and Arousal/Erection. <i>Journal of Sexual Medicine</i> , 2016, 13, 317-337.	0.3	117
9	Central obesity is predictive of persistent storage lower urinary tract symptoms (<scp>LUTS</scp>) after surgery for benign prostatic enlargement: results of a multicentre prospective study. <i>BJU International</i> , 2015, 116, 271-277.	1.3	37
10	Influence of Androgen Receptor CAG Polymorphism on Sexual Function Recovery after Testosterone Therapy in Late-Onset Hypogonadism. <i>Journal of Sexual Medicine</i> , 2015, 12, 381-388.	0.3	14
11	Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. <i>Asian Journal of Andrology</i> , 2014, 16, 295.	0.8	61
12	Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-14.	0.6	96
13	The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-13.	0.6	14
14	Intriguing data on inflammation and prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 369-370.	1.9	24
15	Tadalafil Effect on Metabolic Syndrome-Associated Bladder Alterations: An Experimental Study in a Rabbit Model. <i>Journal of Sexual Medicine</i> , 2014, 11, 1159-1172.	0.3	21
16	Androgen Receptor Gene CAG Repeat Polymorphism Independently Influences Recovery of Male Sexual Function After Testosterone Replacement Therapy in Postsurgical Hypogonadotropic Hypogonadism. <i>Journal of Sexual Medicine</i> , 2014, 11, 1302-1308.	0.3	13
17	A Critical Analysis of the Role of Testosterone in Erectile Function: From Pathophysiology to Treatment—A Systematic Review. <i>European Urology</i> , 2014, 65, 99-112.	0.9	243
18	Injectable testosterone undecanoate for the treatment of hypogonadism. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1903-1926.	0.9	66

#	ARTICLE	IF	CITATIONS
19	Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 107-119.	1.6	83
20	Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. <i>Asian Journal of Andrology</i> , 2014, 16, 767.	0.8	11
21	Testosterone and cardiovascular risk. <i>Internal and Emergency Medicine</i> , 2013, 8, 65-69.	1.0	48
22	Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2013, 168, 829-843.	1.9	343
23	The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia. <i>European Urology</i> , 2013, 63, 506-516.	0.9	128
24	Interleukin 8 and the male genital tract. <i>Journal of Reproductive Immunology</i> , 2013, 100, 54-65.	0.8	83
25	Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit. <i>Prostate</i> , 2013, 73, 428-441.	1.2	72
26	PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS. <i>Prostate</i> , 2013, 73, 1391-1402.	1.2	103
27	Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. <i>Prostate</i> , 2013, 73, 789-800.	1.2	109
28	Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. <i>Journal of Endocrinology</i> , 2012, 212, 71-84.	1.2	165
29	Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. <i>Journal of Endocrinology</i> , 2012, 214, 31-43.	1.2	119
30	Emerging medication for the treatment of male hypogonadism. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 239-259.	1.0	82
31	Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 80-92.	1.2	68
32	A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α -Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. <i>European Urology</i> , 2012, 61, 994-1003.	0.9	286
33	A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10 mg and Tamsulosin 0.4 mg vs. Tamsulosin 0.4 mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Journal of Sexual Medicine</i> , 2012, 9, 1624-1633.	0.3	63
34	How to recognize late-onset hypogonadism in men with sexual dysfunction. <i>Asian Journal of Andrology</i> , 2012, 14, 251-259.	0.8	95
35	Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. <i>European Journal of Endocrinology</i> , 2011, 165, 687-701.	1.9	376
36	Testosterone, cardiovascular disease and the metabolic syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 337-353.	2.2	130

#	ARTICLE	IF	CITATIONS
37	Pulse Pressure Independently Predicts Major Cardiovascular Events in Younger But Not in Older Subjects with Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2011, 8, 247-254.	0.3	23
38	Farnesoid X Receptor Activation Improves Erectile Function in Animal Models of Metabolic Syndrome and Diabetes. <i>Journal of Sexual Medicine</i> , 2011, 8, 57-77.	0.3	74
39	Is Metabolic Syndrome a Useless Category in Subjects with High Cardiovascular Risk? Results from a Cohort Study in Men with Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2011, 8, 504-511.	0.3	14
40	Phosphodiesterase Type 5 Expression in Human and Rat Lower Urinary Tract Tissues and the Effect of Tadalafil on Prostate Gland Oxygenation in Spontaneously Hypertensive Rats. <i>Journal of Sexual Medicine</i> , 2011, 8, 2746-2760.	0.3	130
41	Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. <i>European Urology</i> , 2011, 60, 809-825.	0.9	230
42	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. <i>Neurourology and Urodynamics</i> , 2011, 30, 292-301.	0.8	185
43	Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary Tract. <i>Journal of Sexual Medicine</i> , 2010, 7, 59-69.	0.3	118
44	Vardenafil Improves Erectile Function in Men with Erectile Dysfunction and Associated Underlying Conditions, Irrespective of the Use of Concomitant Medications. <i>Journal of Sexual Medicine</i> , 2010, 7, 244-255.	0.3	20
45	Acute Vardenafil Administration Improves Bladder Oxygenation in Spontaneously Hypertensive Rats. <i>Journal of Sexual Medicine</i> , 2010, 7, 107-120.	0.3	70
46	Male Sexuality and Cardiovascular Risk. A Cohort Study in Patients with Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2010, 7, 1918-1927.	0.3	113
47	Sex Steroid Receptors in Male Human Bladder: Expression and Biological Function. <i>Journal of Sexual Medicine</i> , 2010, 7, 2698-2713.	0.3	66
48	Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 146-152.	1.8	56
49	Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation. <i>Journal of Immunology</i> , 2009, 182, 4056-4064.	0.4	155
50	Pulse Pressure, an Index of Arterial Stiffness, is Associated with Androgen Deficiency and Impaired Penile Blood Flow in Men with ED. <i>Journal of Sexual Medicine</i> , 2009, 6, 285-293.	0.3	61
51	Vardenafil Modulates Bladder Contractility Through cGMP-mediated Inhibition of RhoA/Rho Kinase Signaling Pathway in Spontaneously Hypertensive Rats. <i>Journal of Sexual Medicine</i> , 2009, 6, 1594-1608.	0.3	80
52	The ENDOTRIAL Study: A Spontaneous, Open-Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil, Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2009, 6, 2547-2560.	0.3	52
53	Testosterone Partially Ameliorates Metabolic Profile and Erectile Responsiveness to PDE5 Inhibitors in an Animal Model of Male Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2009, 6, 3274-3288.	0.3	133
54	The vitamin D receptor agonist elocalcitol inhibits IL-6-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF- κ B pathways. <i>Prostate</i> , 2009, 69, 480-493.	1.2	87

#	ARTICLE	IF	CITATIONS
55	Characterization and Functional Role of Androgen-Dependent PDE5 Activity in the Bladder. <i>Endocrinology</i> , 2007, 148, 1019-1029.	1.4	212
56	Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia. <i>European Urology</i> , 2007, 51, 524-533.	0.9	250
57	ORIGINAL RESEARCH "ENDOCRINOLOGY: A Comparison of NCEP-ATPIII and IDF Metabolic Syndrome Definitions with Relation to Metabolic Syndrome-Associated Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2007, 4, 789-796.	0.3	81